AI-powered retinal
disease screening
With the power of AI,
we now have the ability to
Detect
retinal diseases — starting with diabetic retinopathy, with more conditions available on the platform soon
Classify
the severity and progression of the disease with precision
Accelerate
screening times from hours to under 60 seconds
Reduce
misdiagnosis risk with AI-powered clinical accuracy
Discover our screening technology
Scan
Capture high-resolution fundus images with any compatible retinal camera
Analyze
AI processes retinal images using deep learning algorithms trained on thousands of cases
Grade
Automated grading of retinal disease severity — currently supporting diabetic retinopathy, with additional diseases coming soon
Report
Instant clinical reports with actionable recommendations for patient care
Explore Eyequno
Empower your practice with AI-assisted retinal disease screening — starting with diabetic retinopathy — that delivers accurate grading results in under 60 seconds.
Why EyeQuno
Ophthalmic hospitals in South America are under serious strain — wait times exceed a year, millions of patients lack early retinal screening, and 36.3% of Brazilian diabetics have diabetic retinopathy. EyeQuno addresses this with a commercially ready, LATAM-first AI diagnostic platform.
01 — Higher Revenue
Increase Patient Volume & Hospital Revenue
With increased patient intake and higher quality of care, the overall experience and volume will drive hospital revenue up.
02 — Lower Liability
Reduce Diagnostic Risk & Legal Exposure
Misdiagnosis due to exhausted doctors and sheer patient volume leaves hospitals liable to lawsuits. EyeQuno acts as a second set of eyes, ensuring greater diagnostic safety.
03 — Better Prioritization
Triage Patients by Urgency, Not Arrival Order
Creating the right priority allows for better patient care. It also pushes towards a positive reputation based on patient needs and urgency — ensuring the most critical cases are treated first.
Ophthalmic hospitals in South America face over a year of wait times, limited retinal screening access, and a growing diabetic retinopathy burden. EyeQuno’s AI platform is built to solve this.
1 year+
wait times at ophthalmic hospitals in South America
36.3%
of Brazilian diabetics have diabetic retinopathy
Millions
of patients lack access to early retinal screening
<60s
to analyze a fundus image with EyeQuno’s AI engine
45
paying hospitals targeted by January 2027
100+
partner clinics and hospitals targeted across Latin America by 2028
Jun 2026 — MVP Deployment in 3 Brazilian Hospitals
EyeQuno deploys its MVP in three hospitals in Brazil, beginning real-world AI-assisted retinal diagnostics and collecting feedback to improve the model.
Jul 2026 — Beta Expansion to 8 Hospitals
After iterating on the model to achieve the highest diagnostic accuracy, EyeQuno expands to eight beta-testing hospitals across Brazil.
Aug 2026 — Full Launch & Multi-Disease Expansion
EyeQuno moves to a full commercial launch with support for multiple retinal pathologies, scaling its AI diagnostic platform across the region.
This is AI-powered retinal screening.
This is the future of eye care.
This site is protected by reCAPTCHA.